Real‐World Data From the Joint Psoriasis—Psoriatic Arthritis Clinic ( PPAC ) on the Efficacy of Bimekizumab in Patients With Psoriasis and Psoriatic Arthritis

银屑病 银屑病性关节炎 医学 皮肤病科 关节炎 免疫学
作者
George Vaiopoulos,Ioannis Michelakis,Pelagia Katsimbri,Kyriaki Lampadaki,Dimitrios Katsifis,Elena Sabatakaki,Dimitrios D. Tseronis,Konstantina Zoupidou,Alexander Katoulis,Evangelia Papadavid
出处
期刊:International Journal of Dermatology [Wiley]
卷期号:64 (10): 1926-1929 被引量:3
标识
DOI:10.1111/ijd.17654
摘要

PPAC, the first dual care clinic in Greece for psoriasis (PsO) and psoriatic arthritis (PsA) patients, has been based at Attikon General University Hospital, where dermatologists and rheumatologists cooperate and provide care for patients with severe, recalcitrant disease, and multiple comorbidities [1]. At the joint PPAC clinic, we have the advantage of testing the efficacy of bimekizumab in a case series of PsO patients with recalcitrant PsA with peripheral and axial manifestations who failed several previously available biologic treatments, including interleukin (IL)-17A and IL-23 inhibitors from April 1, 2023, to December 31, 2023, prior to the official approval of bimekizumab in PsA [2, 3]. This study was carried out in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice. All study participants gave informed consent. Successfully switching to bimekizumab in recalcitrant PsO patients who previously have received other IL-17A or 23 inhibitors has been investigated in several studies [4]. However, there is only one small case series on the efficacy of switching biologics within the same class or from IL-23 inhibitors in patients with recalcitrant PsA [5]. The demographic and baseline clinical characteristics, as well as treatment outcomes of six patients, are summarized in Table 1: 5/6 with peripheral joint involvement manifesting as polyarthritis, 1/6 with axial participation, 4/6 with nail involvement, 1/6 with scalp psoriasis, 3/6 were treatment naïve, and 3/6 patients were bioexperienced and switched to bimekizumab due to secondary failure in both skin and joint involvement, from another IL-17A inhibitor (ixekizumab), IL-23 p19 blocker guselkumab and upadacitinib. Evaluation of absolute PASI (aPASI), Disease Activity Index for Psoriatic Arthritis (DAPSA), and Axial Spondyloarthritis Disease Activity Score (ASDAS) at Week 24 were the primary endpoints. PASI, DAPSA, ASDAS, PGA, and ΔPASI 75/90/100 were significantly improved at Week 24 (Figure 1a,b). All patients reached ΔPASI 75 and ΔPASI 90 at Week 24, whereas 5 out of 6 presented PASI < 3. The quick onset of action of bimekizumab (mean aPASI from 11.67 was reduced to 0.43 at Week 24, respectively) drags along DLQI (mean value of 17.17 at baseline to 2 at Week 24, respectively). Joint manifestations also presented a significant improvement but slower than skin manifestations (mean baseline DAPSA of 23.9 was reduced to 12.42 after 16 weeks and further decreased at a mean value of 6 up to Week 24). At Week 24, 3 out of 5 patients with peripheral arthritis achieved remission (DAPSA ≤ 4), and in the patient with only axial involvement, baseline ASDAS was reduced from 2.5 to 1.4. Bioexperienced patients had significantly higher DAPSA values at treatment start, while no differences in PASI score or other clinical characteristics could be demonstrated between bio-naïve and bio-experienced patients. All patients reached the 24-week observation endpoint, and no major safety signals responsible for drug discontinuation were recorded. No statistically significant differences were found in terms of clinical response in both skin and joint involvement regarding body mass index (BMI), smoking habits, and comorbidities. Despite the small sample size, it seemed that patients with disease onset at earlier age/longer disease duration had lower rates of achieving PASI < 3 at Weeks 16 and 24 and attaining PASI75 at Week 4. Our data confirm the efficacy and safety of bimekizumab in treating PsO and PsA patients recalcitrant to other cytokines inhibitors, IL-17A and IL-23 p19. The majority of patients achieved clear or almost clear skin and significant improvement of arthritis, starting from Week 4, with a maximal effect at Week 24. The small sample size does not allow the comparison between bio-naive and bio-experienced patients, however, bimekizumab was proven efficacious in both skin and joint manifestations regardless of previous treatment status, confirming the results from clinical trials and real-world studies [2-5]. Despite the relatively short follow-up time, this study exerts the advantages of PPAC to a better and more sustainable treatment of difficult cases with PsA/PsO. Long-term real-life studies are important to further evaluate the safety and efficacy of bimekizumab in PsA treatment. The authors declare no conflicts of interest.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wanci的应助被LKX采纳,获得10
刚刚
高挑的葵阴完成签到,获得积分10
刚刚
xh完成签到 ,获得积分10
刚刚
ljy0825完成签到 ,获得积分10
刚刚
Orange的应助被quhayley采纳,获得10
刚刚
无声瀑布完成签到,获得积分10
1秒前
稀饭完成签到,获得积分10
1秒前
1秒前
null的应助被科研通管家采纳,获得10
1秒前
1秒前
邓力的应助被科研通管家采纳,获得10
1秒前
树池完成签到,获得积分10
1秒前
邓力的应助被科研通管家采纳,获得10
1秒前
情怀的应助被科研通管家采纳,获得30
2秒前
爆米花的应助被biotech_soldier采纳,获得10
2秒前
完美世界的应助被科研通管家采纳,获得10
2秒前
丘比特的应助被科研通管家采纳,获得10
2秒前
null的应助被科研通管家采纳,获得10
2秒前
略略略完成签到,获得积分0
2秒前
派大星完成签到,获得积分10
3秒前
3秒前
清爽盼秋发布了新的文献求助10
3秒前
beichen完成签到,获得积分10
4秒前
俊鱼完成签到,获得积分10
4秒前
ok123完成签到 ,获得积分10
4秒前
Sara_123完成签到,获得积分10
4秒前
张思哲完成签到,获得积分10
4秒前
李琪完成签到 ,获得积分10
6秒前
palette完成签到,获得积分10
6秒前
6秒前
落雁完成签到 ,获得积分10
6秒前
江上完成签到 ,获得积分10
6秒前
ovalCC完成签到,获得积分10
6秒前
xiejuan完成签到,获得积分0
7秒前
平城时代完成签到,获得积分10
7秒前
mimosa发布了新的文献求助10
7秒前
7秒前
lic完成签到,获得积分10
7秒前
7秒前
脑洞疼的应助被宗佳茹采纳,获得10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159288
求助须知:如何正确求助?哪些是违规求助? 9554702
关于积分的说明 21720900
捐赠科研通 7748911
什么是DOI,文献DOI怎么找? 3427184
关于科研通互助平台的介绍 2552111
邀请新用户注册赠送积分活动 2471479